Temporal profiles of blood pressure, circulating nitric oxide, and adrenomedullin as predictors of clinical outcome in acute ischemic stroke patients

What Was Tested

Researchers studied Adrenomedullin in the context of low blood pressure and orthostatic hypotension in this clinical trial publication.

Stroke remains an important health and social challenge.

The present study investigated whether blood pressure (BP) parameters and circulating levels of nitric oxide metabolites (NOx) and adrenomedullin (AM) may predict clinical outcomes of stroke.

Who Took Part

The abstract describes 2 individuals taking part.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

Infarct volume, neurological severity [on the National Institutes of Health Stroke Scale (NIHSS)], and functional prognosis (on the Rankin scale) were measured as clinical outcomes.

What Was Measured

The present study investigated whether blood pressure (BP) parameters and circulating levels of nitric oxide metabolites (NOx) and adrenomedullin (AM) may predict clinical outcomes of stroke.

Blood plasma was collected at days 1, 2, and 7 to measure NOx and AM levels.

PubMed files the paper under topics including Acute Disease, Adrenomedullin, Blood Pressure, Brain Ischemia, Disease-Free Survival, Nitric Oxide and Stroke.

What This Means in Plain Language

This is a clinical trial of Adrenomedullin in 2 individuals in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2016 (Molecular medicine reports), a journal based in Greece.

More context: the Adrenomedullin compound page, Low blood pressure and orthostatic hypotension research.